Shire Stock Price, News & Analysis (LON:SHP)

GBX 3,024 -13.00 (-0.43 %)
(As of 02/23/2018 04:00 PM ET)
Previous CloseGBX 3,024
Today's RangeGBX 3,002 - GBX 3,125
52-Week RangeGBX 2,940.50 - GBX 5,067
Volume2.75 million shs
Average Volume3.15 million shs
Market Capitalization£27.44 billion
P/E Ratio2,085.52
Dividend YieldN/A
BetaN/A

About Shire (LON:SHP)

Shire logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive SHP News and Ratings via Email

Sign-up to receive the latest news and ratings for SHP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolLON:SHP
CUSIPN/A
Phone+353-1-6096000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio2085.51724137931
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX 1.45
Net IncomeN/A
Net Margins15.00%
Return on Equity6.92%
Return on Assets3.30%

Miscellaneous

EmployeesN/A
Outstanding Shares908,640,000

Shire (LON:SHP) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the London Stock Exchange (LON) under the ticker symbol "SHP."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire declared a dividend on Wednesday, February 14th. Investors of record on Thursday, March 8th will be paid a dividend of GBX 21.46 per share on Tuesday, April 24th. This represents a yield of 0.67%. The ex-dividend date is Thursday, March 8th. This is an increase from Shire's previous dividend of $3.85. The official announcement can be viewed at this link. View Shire's Dividend History.

Where is Shire's stock going? Where will Shire's stock price be in 2018?

17 Wall Street analysts have issued 12-month price objectives for Shire's shares. Their predictions range from GBX 3,600 to GBX 8,000. On average, they anticipate Shire's stock price to reach GBX 5,043.75 in the next twelve months. View Analyst Ratings for Shire.

Who are some of Shire's key competitors?

Who are Shire's key executives?

Shire's management team includes the folowing people:

  • Flemming Ornskov M.D., Chief Executive Officer, Executive Director (Age 59)
  • John Miller, Interim Chief Financial Officer
  • Joanne Cordeiro, Chief Human Resource Officer
  • Andreas Busch Ph.D., Executive Vice President - Head of Research and Development, Chief Scientific Officer (Age 54)
  • Gisele Dion, Chief Accounting Officer, Corporate Controller (Age 51)
  • William Mordan, General Counsel, Company Secretary (Age 47)
  • Howard Mayer M.D., Chief Medical Officer
  • Perry Sternberg, Head - U.S. Commercial (Age 48)
  • Kim Stratton, Head - International Commercial (Age 56)
  • Philip J. Vickers, Head - Research and Development (Age 56)

How do I buy Shire stock?

Shares of Shire and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Shire's stock price today?

One share of Shire stock can currently be purchased for approximately GBX 3,024.

How big of a company is Shire?

Shire has a market capitalization of £27.44 billion.

How can I contact Shire?

Shire's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000.


MarketBeat Community Rating for Shire (SHP)

Community Ranking:  4.1 out of 5 (star star star star)
Outperform Votes:  1,177 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  1,450
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire (LON:SHP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.822.882.942.94
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: GBX 5,043.75GBX 5,156.67GBX 5,340.63GBX 6,052.27

Shire (LON:SHP) Consensus Price Target History

Price Target History for Shire (LON:SHP)

Shire (LON:SHP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/23/2018Shore CapitalReiterated RatingBuyView Rating Details
2/23/2018Berenberg BankLower Price TargetBuyGBX 6,000 -> GBX 4,500View Rating Details
2/21/2018CitigroupReiterated RatingBuyGBX 5,500View Rating Details
2/20/2018JPMorgan Chase & Co.DowngradeNeutralGBX 5,000 -> GBX 3,600View Rating Details
2/15/2018Morgan StanleyReiterated RatingOverweightGBX 5,700View Rating Details
2/15/2018Kepler Capital MarketsReiterated RatingBuyGBX 4,600View Rating Details
2/15/2018BarclaysReiterated RatingEqual weightGBX 3,650View Rating Details
2/15/2018Deutsche BankLower Price TargetBuyGBX 5,000 -> GBX 4,500View Rating Details
2/15/2018Credit Suisse GroupLower Price TargetOutperformGBX 4,500 -> GBX 4,000View Rating Details
2/14/2018Liberum CapitalReiterated RatingHoldGBX 4,000View Rating Details
1/29/2018InvestecReiterated RatingBuyGBX 8,000View Rating Details
1/29/2018Societe GeneraleReiterated RatingBuyGBX 8,000View Rating Details
1/16/2018BNP ParibasReiterated RatingOutperformGBX 4,700View Rating Details
11/24/2017Goldman Sachs GroupReiterated RatingConviction-BuyGBX 6,000View Rating Details
11/21/2017HSBCLower Price TargetHoldGBX 4,050 -> GBX 3,800View Rating Details
11/17/2017Royal Bank of CanadaReiterated RatingOutperformView Rating Details
8/22/2017Jefferies GroupReiterated RatingBuyView Rating Details
8/4/2017Beaufort SecuritiesReiterated RatingLong Term BuyGBX 6,200 -> GBX 4,900View Rating Details
1/9/2017Bryan, Garnier & CoReiterated RatingBuyGBX 6,800View Rating Details
11/7/2016AlphaValueReiterated RatingBuyGBX 6,714View Rating Details
11/3/2016Bank of AmericaReiterated RatingBuyGBX 6,970View Rating Details
3/15/2016Sanford C. BernsteinReiterated RatingOutperformGBX 5,000View Rating Details
(Data available from 2/24/2016 forward)

Earnings

Earnings History for Shire (LON:SHP)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Shire (LON:SHP) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Shire (LON:SHP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/14/2018GBX 21.460.67%3/8/20183/8/20184/24/2018
8/3/2017GBX 3.850.1%9/7/20179/7/201710/20/2017
2/16/2017GBX 20.640.43%3/9/20173/9/20174/25/2017
8/2/2016GBX 3.510.07%9/8/20169/8/201610/7/2016
2/11/2016GBX 15.320.44%3/10/20163/10/20164/12/2016
7/23/2015GBX 2.690.05%9/3/20159/3/201510/2/2015
7/18/2014GBX 2.240.04%9/3/20149/3/201410/3/2014
2/13/2014GBX 10.210.31%3/5/20143/5/20144/8/2014
(Data available from 1/1/2013 forward)

Insider Trades

Shire (LON SHP) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Shire (LON:SHP)

Shire (LON SHP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/19/2017Dominic BlakemoreInsiderBuy165GBX 3,790£6,253.50
9/29/2017Anne MintoInsiderBuy190GBX 3,785£7,191.50
8/22/2017Flemming OrnskovInsiderBuy8,400GBX 3,665£307,860
6/30/2017Dominic BlakemoreInsiderBuy152GBX 4,255£6,467.60
3/31/2017William BurnsInsiderBuy136GBX 4,742£6,449.12
12/16/2016Olivier BohuonInsiderBuy141GBX 4,528£6,384.48
9/30/2016Dominic BlakemoreInsiderBuy133GBX 5,010£6,663.30
6/30/2016Bohuon,OlivierInsiderBuy134GBX 4,463£5,980.42
3/31/2016Bohuon,OlivierInsiderBuy133GBX 3,908£5,197.64
2/15/2016Bohuon,OlivierInsiderBuy1,000GBX 3,552£35,520
2/12/2016Burns,WilliamInsiderBuy1,250GBX 3,563£44,537.50
12/18/2015Burns,WilliamInsiderBuy156GBX 4,457£6,952.92
9/30/2015Blakemore ,DominicInsiderBuy129GBX 4,498£5,802.42
6/30/2015Kappler,David JInsiderBuy126GBX 51.05GBX 6,432.30
3/31/2015Susan KilsbyInsiderBuy375GBX 5,327£19,976.25
12/19/2014Steven GillisInsiderBuy228GBX 4,654£10,611.12
10/30/2014Steven GillisInsiderBuy381GBX 4,098£15,613.38
(Data available from 1/1/2013 forward)

Headlines

Shire (LON SHP) News Headlines

Source:
DateHeadline
Shire Recognizes Rare Disease Day 2018 with Global Initiatives Focused on Reducing the Time to Diagnosis - GlobeNewswire (press release)Shire Recognizes Rare Disease Day 2018 with Global Initiatives Focused on Reducing the Time to Diagnosis - GlobeNewswire (press release)
globenewswire.com - February 22 at 8:30 AM
Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases - GlobeNewswire (press release)Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases - GlobeNewswire (press release)
globenewswire.com - February 22 at 8:30 AM
Shire to Present Data at 2018 AAAAI/WAO Joint Congress ... - GlobeNewswire (press release)Shire to Present Data at 2018 AAAAI/WAO Joint Congress ... - GlobeNewswire (press release)
globenewswire.com - February 21 at 8:31 AM
Shire (SHP) PT Lowered to GBX 4,000 at Credit Suisse GroupShire (SHP) PT Lowered to GBX 4,000 at Credit Suisse Group
www.americanbankingnews.com - February 18 at 12:42 AM
Deutsche Bank Trims Shire (SHP) Target Price to GBX 4,500Deutsche Bank Trims Shire (SHP) Target Price to GBX 4,500
www.americanbankingnews.com - February 18 at 12:42 AM
Shire (SHP) Rating Reiterated by BarclaysShire (SHP) Rating Reiterated by Barclays
www.americanbankingnews.com - February 18 at 12:10 AM
Shire (SHP) Receives "Buy" Rating from Kepler Capital MarketsShire (SHP) Receives "Buy" Rating from Kepler Capital Markets
www.americanbankingnews.com - February 17 at 9:22 PM
With A Recent ROE Of 4.97%, Can Shire plc (NASDAQ:SHPG) Catch Up To Its Industry?With A Recent ROE Of 4.97%, Can Shire plc (NASDAQ:SHPG) Catch Up To Its Industry?
finance.yahoo.com - February 15 at 5:14 PM
Morgan Stanley Reaffirms Overweight Rating for Shire (SHP)Morgan Stanley Reaffirms Overweight Rating for Shire (SHP)
www.americanbankingnews.com - February 15 at 2:08 PM
Shire Q4 Profit Surges On U.S. Tax Reform; Sees 2018 Profit Below ... - NasdaqShire Q4 Profit Surges On U.S. Tax Reform; Sees 2018 Profit Below ... - Nasdaq
www.nasdaq.com - February 15 at 8:14 AM
Shire Provides Regulatory Progress Update for Key Pipeline Programs Targeting Rare Disease - GlobeNewswire (press release)Shire Provides Regulatory Progress Update for Key Pipeline Programs Targeting Rare Disease - GlobeNewswire (press release)
globenewswire.com - February 15 at 8:14 AM
CORRECTION - Shire Announces FDA Acceptance of sBLA for CINRYZE® for Pediatric Hereditary Angioedema Use - GlobeNewswire (press release)CORRECTION - Shire Announces FDA Acceptance of sBLA for CINRYZE® for Pediatric Hereditary Angioedema Use - GlobeNewswire (press release)
globenewswire.com - February 15 at 8:14 AM
Shire Announces FDA Acceptance of sBLA for CINRYZE® for Pediatric Hereditary Angioedema Use - GlobeNewswire (press release)Shire Announces FDA Acceptance of sBLA for CINRYZE® for Pediatric Hereditary Angioedema Use - GlobeNewswire (press release)
globenewswire.com - February 15 at 8:14 AM
Shires (SHP) Hold Rating Reiterated at Liberum CapitalShire's (SHP) Hold Rating Reiterated at Liberum Capital
www.americanbankingnews.com - February 14 at 8:52 PM
Shire PLC (SHP) Given Average Recommendation of "Buy" by AnalystsShire PLC (SHP) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 10 at 11:40 AM
Shire (SHP) Coverage Initiated by Analysts at BarclaysShire (SHP) Coverage Initiated by Analysts at Barclays
www.americanbankingnews.com - February 4 at 4:28 PM
Shires (SHP) Buy Rating Reiterated at InvestecShire's (SHP) Buy Rating Reiterated at Investec
www.americanbankingnews.com - January 29 at 5:00 PM
Shire (SHP) Receives Buy Rating from Societe GeneraleShire (SHP) Receives Buy Rating from Societe Generale
www.americanbankingnews.com - January 29 at 9:25 AM
FDA Grants Approval to Shire for Technology Transfer of CINRYZE ... - GlobeNewswire (press release)FDA Grants Approval to Shire for Technology Transfer of CINRYZE ... - GlobeNewswire (press release)
globenewswire.com - January 24 at 8:13 AM
Shire Continues to Uphold High Standards of Ethics and Transparency with Adoption of Open Access Policy for ... - GlobeNewswire (press release)Shire Continues to Uphold High Standards of Ethics and Transparency with Adoption of Open Access Policy for ... - GlobeNewswire (press release)
globenewswire.com - January 24 at 8:13 AM
Shire PLC (SHP) Receives Consensus Recommendation of "Buy" from BrokeragesShire PLC (SHP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 16 at 9:56 AM
Shire (SHP) Given Buy Rating at Shore CapitalShire (SHP) Given Buy Rating at Shore Capital
www.americanbankingnews.com - January 16 at 12:40 AM
Shire (SHP) Given Buy Rating at Deutsche BankShire (SHP) Given Buy Rating at Deutsche Bank
www.americanbankingnews.com - January 11 at 6:46 AM
Shire To Operate As Two Divisions: Rare Disease And Neuroscience - NasdaqShire To Operate As Two Divisions: Rare Disease And Neuroscience - Nasdaq
www.nasdaq.com - January 9 at 4:40 PM
Shire announces reorganization, sets sales targetShire announces reorganization, sets sales target
www.marketwatch.com - January 8 at 4:43 PM
Citigroup Reiterates Buy Rating for Shire (SHP)Citigroup Reiterates Buy Rating for Shire (SHP)
www.americanbankingnews.com - January 7 at 1:28 PM
Shire to present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Shire to present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
www.globenewswire.com - January 4 at 10:13 AM
Shire plc : Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for ... - GlobeNewswire (press release)Shire plc : Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for ... - GlobeNewswire (press release)
globenewswire.com - January 4 at 10:13 AM
Shires dry eye treatment approved in CanadaShire's dry eye treatment approved in Canada
www.marketwatch.com - January 3 at 9:34 AM
Shire (SHP) Given "Buy" Rating at Shore CapitalShire (SHP) Given "Buy" Rating at Shore Capital
www.americanbankingnews.com - December 31 at 7:25 PM
Shire (SHP) Price Target Increased to GBX 8,000 by Analysts at Societe GeneraleShire (SHP) Price Target Increased to GBX 8,000 by Analysts at Societe Generale
www.americanbankingnews.com - December 31 at 9:46 AM
Healthcare: Pick Carefully as Valuations Head HigherHealthcare: Pick Carefully as Valuations Head Higher
finance.yahoo.com - December 28 at 8:52 AM
Shire Files For FDA Approval Of Plasma Manufacturing Facility In ... - NasdaqShire Files For FDA Approval Of Plasma Manufacturing Facility In ... - Nasdaq
www.nasdaq.com - December 27 at 1:06 PM
Shire: If You Build It…Shire: If You Build It…
finance.yahoo.com - December 27 at 1:06 PM
Will Shire plc’s (LON:SHP) Earnings Grow Over The Next Few Years?Will Shire plc’s (LON:SHP) Earnings Grow Over The Next Few Years?
finance.yahoo.com - December 25 at 6:09 PM
Shire (SHP) Earns Buy Rating from Deutsche BankShire (SHP) Earns Buy Rating from Deutsche Bank
www.americanbankingnews.com - December 25 at 10:46 AM
Shire (SHP) Rating Lowered to Hold at Liberum CapitalShire (SHP) Rating Lowered to Hold at Liberum Capital
www.americanbankingnews.com - December 23 at 10:00 PM
Shire PLC (SHP) Given Consensus Rating of "Buy" by AnalystsShire PLC (SHP) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - December 22 at 10:30 AM
Shire PLC (SHP) Insider Dominic Blakemore Buys 165 SharesShire PLC (SHP) Insider Dominic Blakemore Buys 165 Shares
www.americanbankingnews.com - December 20 at 8:24 AM
UPDATE: Shire SHP609 Trial Misses, myPKFiT Cleared By FDAUPDATE: Shire SHP609 Trial Misses, myPKFiT Cleared By FDA
www.morningstar.co.uk - December 19 at 4:35 PM
Shire plc : Novel Clinical Study Collaboration Announced Designed ... - GlobeNewswire (press release)Shire plc : Novel Clinical Study Collaboration Announced Designed ... - GlobeNewswire (press release)
globenewswire.com - December 14 at 5:07 PM
Shire: ONCASPAR Formulation Receives Marketing Authorization In EuropeShire: ONCASPAR Formulation Receives Marketing Authorization In Europe
www.rttnews.com - December 13 at 10:40 AM
Shire Plc breached its 50 day moving average in a Bullish Manner : SHP-GB : December 12, 2017Shire Plc breached its 50 day moving average in a Bullish Manner : SHP-GB : December 12, 2017
finance.yahoo.com - December 12 at 10:45 AM
Shire names John Miller interim CFOShire names John Miller interim CFO
www.marketwatch.com - December 9 at 10:18 AM
Shire (SHP) Given Buy Rating at CitigroupShire (SHP) Given Buy Rating at Citigroup
www.americanbankingnews.com - December 8 at 10:34 AM
Shire names new chief scientific, medical officersShire names new chief scientific, medical officers
www.marketwatch.com - December 1 at 5:36 PM
Shire (SHP) Receives Overweight Rating from Morgan StanleyShire (SHP) Receives Overweight Rating from Morgan Stanley
www.americanbankingnews.com - December 1 at 6:43 AM
Shire PLC (SHP) Rating Reiterated by Liberum CapitalShire PLC (SHP) Rating Reiterated by Liberum Capital
www.americanbankingnews.com - November 26 at 12:08 AM
Liberum Capital Reaffirms Buy Rating for Shire PLC (SHP)Liberum Capital Reaffirms Buy Rating for Shire PLC (SHP)
www.americanbankingnews.com - November 24 at 7:28 PM
Deutsche Bank AG Reiterates Buy Rating for Shire PLC (SHP)Deutsche Bank AG Reiterates Buy Rating for Shire PLC (SHP)
www.americanbankingnews.com - November 24 at 6:04 PM

SEC Filings

Shire (LON:SHP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Shire (LON SHP) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.